Abstract
SUMMARY: There is increasing use of neuroimaging modalities, including PET, for diagnosing dementia. For example, FDG-PET demonstrates hypometabolic regions in the posterior cingulate gyri, precuneus, and parietotemporal association cortices, while amyloid PET indicates amyloid deposition in Alzheimer disease and mild cognitive impairment due to Alzheimer disease. Furthermore, the use of combination PET with structural MR imaging can improve the diagnostic accuracy of dementia. In other neurodegenerative dementias, each disease exhibits a specific metabolic reduction pattern. In dementia with Lewy bodies, occipital glucose metabolism is decreased, while in frontotemporal dementia, frontal and anterior temporal metabolism is predominantly decreased. These FDG-PET findings and positive or negative amyloid deposits are important biomarkers for various neurodegenerative dementias.
ABBREVIATIONS:
- Aβ
- amyloid β peptide
- AD
- Alzheimer disease
- APOE
- apolipoprotein E
- CBD
- corticobasal degeneration
- DLB
- dementia with Lewy bodies
- FTD
- frontotemporal dementia
- MCI
- mild cognitive impairment
- PD
- Parkinson disease
- PiB
- Pittsburgh compound-B
- PSP
- progressive supranuclear palsy
- VBM
- voxel-based morphometry
- © 2014 by American Journal of Neuroradiology
Indicates open access to non-subscribers at www.ajnr.org